Suppr超能文献

包含立体定义的 P2' 配体以优化底物信封中氢键的 HIV-1 蛋白酶抑制剂。

HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.

机构信息

Department of Biochemistry and Molecular Pharmacology , University of Massachusetts Medical School , Worcester , Massachusetts 01605 , United States.

Department of Biochemistry and Biophysics, and the UNC Center for AIDS Research , University of North Carolina at Chapel Hill , Chapel Hill , North Carolina 27599 , United States.

出版信息

J Med Chem. 2019 Sep 12;62(17):8062-8079. doi: 10.1021/acs.jmedchem.9b00838. Epub 2019 Aug 21.

Abstract

A structure-guided design strategy was used to improve the resistance profile of HIV-1 protease inhibitors by optimizing hydrogen bonding and van der Waals interactions with the protease while staying within the substrate envelope. Stereoisomers of 4-(1-hydroxyethyl)benzene and 4-(1,2-dihydroxyethyl)benzene moieties were explored as P2' ligands providing pairs of diastereoisomers epimeric at P2', which exhibited distinct potency profiles depending on the configuration of the hydroxyl group and size of the P1' group. While compounds with the 4-(1-hydroxyethyl)benzene P2' moiety maintained excellent antiviral potency against a panel of multidrug-resistant HIV-1 strains, analogues with the polar 4-(1,2-dihydroxyethyl)benzene moiety were less potent, and only the ()-epimer incorporating a larger 2-ethylbutyl P1' group showed improved potency. Crystal structures of protease-inhibitor complexes revealed strong hydrogen bonding interactions of both ()- and ()-stereoisomers of the hydroxyethyl group with Asp30'. Notably, the ()-dihydroxyethyl group was involved in a unique pattern of direct hydrogen bonding interactions with the backbone amides of Asp29' and Asp30'. The SAR data and analysis of crystal structures provide insights for optimizing these promising HIV-1 protease inhibitors.

摘要

采用基于结构的设计策略,通过优化与蛋白酶的氢键和范德华相互作用,同时保持在底物包埋范围内,来改善 HIV-1 蛋白酶抑制剂的耐药性特征。探索了 4-(1-羟乙基)苯和 4-(1,2-二羟乙基)苯部分的立体异构体作为 P2' 配体,提供了在 P2'处具有对映异构体的非对映异构体对,其活性谱取决于羟基的构型和 P1'基团的大小。虽然具有 4-(1-羟乙基)苯 P2'部分的化合物对多种耐药性 HIV-1 株保持了优异的抗病毒活性,但具有极性 4-(1,2-二羟乙基)苯部分的类似物活性较低,只有包含较大 2-乙基丁基 P1'基团的 ()-对映异构体显示出改善的活性。蛋白酶-抑制剂复合物的晶体结构揭示了羟乙基的 ()-和 ()-立体异构体与 Asp30'之间的强氢键相互作用。值得注意的是,()-二羟乙基基团与 Asp29'和 Asp30'的骨架酰胺之间存在独特的直接氢键相互作用模式。SAR 数据和晶体结构分析为优化这些有前途的 HIV-1 蛋白酶抑制剂提供了见解。

相似文献

1
HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
J Med Chem. 2019 Sep 12;62(17):8062-8079. doi: 10.1021/acs.jmedchem.9b00838. Epub 2019 Aug 21.
6
Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants.
Eur J Med Chem. 2021 Aug 5;220:113450. doi: 10.1016/j.ejmech.2021.113450. Epub 2021 Apr 20.
7
Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.
Bioorg Med Chem Lett. 2019 Feb 1;29(3):357-361. doi: 10.1016/j.bmcl.2018.12.040. Epub 2018 Dec 18.
10
Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite.
Bioorg Med Chem. 2020 Aug 15;28(16):115623. doi: 10.1016/j.bmc.2020.115623. Epub 2020 Jul 3.

引用本文的文献

6
Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance.
Chem Commun (Camb). 2022 Oct 20;58(84):11762-11782. doi: 10.1039/d2cc04541a.
7
Viral proteases: Structure, mechanism and inhibition.
Enzymes. 2021;50:301-333. doi: 10.1016/bs.enz.2021.09.004. Epub 2021 Nov 17.
8
A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
Eur J Med Chem. 2021 Apr 5;215:113267. doi: 10.1016/j.ejmech.2021.113267. Epub 2021 Feb 10.
9
Inhibiting HTLV-1 Protease: A Viable Antiviral Target.
ACS Chem Biol. 2021 Mar 19;16(3):529-538. doi: 10.1021/acschembio.0c00975. Epub 2021 Feb 23.
10
Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.
Chem Rev. 2021 Mar 24;121(6):3238-3270. doi: 10.1021/acs.chemrev.0c00648. Epub 2021 Jan 7.

本文引用的文献

1
Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.
ACS Infect Dis. 2019 Feb 8;5(2):316-325. doi: 10.1021/acsinfecdis.8b00336. Epub 2018 Dec 31.
2
Sub-picomolar Inhibition of HIV-1 Protease with a Boronic Acid.
J Am Chem Soc. 2018 Oct 31;140(43):14015-14018. doi: 10.1021/jacs.8b07366. Epub 2018 Oct 22.
8
Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
ChemMedChem. 2017 Dec 7;12(23):1942-1952. doi: 10.1002/cmdc.201700614. Epub 2017 Nov 24.
10
Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.
J Infect Dis. 2017 Dec 1;216(suppl_9):S843-S846. doi: 10.1093/infdis/jix398.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验